Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Inactivated Hepatitis A Vaccine (Human Diploid Cell) (1 mL)
Inactivated Hepatitis A Vaccine · 1 trial · 1 indication
The seroconversion rate of anti-hepatitis A virus (HAV) antibodies 30 days after the second vaccination
| Arm | Type | Description |
|---|---|---|
| Adult dose, treatment group (≥16 years) | EXPERIMENTAL | - |
| Pediatric dose, treatment group (6~ <16 years) | EXPERIMENTAL | - |
| Pediatric dose, control group (6~ <16 years) | ACTIVE_COMPARATOR | - |
| Pediatric dose, treatment group (1~ <6 years) | EXPERIMENTAL | - |
| Pediatric dose, conrol group (1~ <6 years) | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Inactivated Hepatitis A Vaccine (Human Diploid Cell) (1 mL) | BIOLOGICAL | Inactivated Hepatitis A Vaccine (Human Diploid Cell) manufactured by Sinovac, adult dose (≥ 16 years) |
| Inactivated Hepatitis A Vaccine (Human Diploid Cell) (0.5 mL) | BIOLOGICAL | Inactivated Hepatitis A Vaccine (Human Diploid Cell) manufactured by Sinovac, pediatric dose (1\~\<16 years) |
| Hepatitis A vaccine (inactivated, adsorbed) | BIOLOGICAL | Hepatitis A vaccine (inactivated, adsorbed) manufactured by Sanofi |
Inclusion Criteria: 1. Healthy participants aged 1 year and older; 2. Participants (and/or their legal guardians) are able to understand and sign the informed consent voluntarily; 3. Participants of reproductive potential and their sexual partners should voluntarily use effective contraception from...